GeoVax Granted European Patent Titled ‘COMPOSITIONS AND METHODS FOR GENERATING AN IMMUNE RESPONSE TO A TUMOR ASSOCIATED ANTIGEN’
https://register.epo.org/application?number=EP17736506
Dawson James Initiates Coverage On Geovax Labs with Buy Rating, Announces Price Target of $4
Dawson James analyst Jason Kolbert initiates coverage on Geovax Labs (NASDAQ:GOVX) with a Buy rating and announces Price Target of $4.
HC Wainwright & Co. Reiterates Buy on Geovax Labs, Maintains $8 Price Target
HC Wainwright & Co. analyst Vernon Bernardino reiterates Geovax Labs (NASDAQ:GOVX) with a Buy and maintains $8 price target.
Why Top Ships Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Amesite Inc. (NASDAQ: AMST) shares jumped 123% to $0.6284 after the company announced GPT-3 powered functionality to its AI toolkit for customers and users.
Why Applied UV Shares Are Trading Higher By 46%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Gainers
FOXO Technologies Inc. (NYSE: FOXO) shares jumped 109% to $1.07.
Akanda Corp. (NASDAQ: AKAN) rose 59% to $0.4459 after jumping 47% on Thursday.
Why GeneDx Holdings Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket
Gainers
Freightos Limited (NASDAQ: CRGO) shares rose 69.2% to $17.75 in pre-market trading. Freightos listed on the Nasdaq following merger with special purpose acquisition company, Gesher I Acquisition Corp.
GeoVax Receives Notice of Allowance For Zika Vaccine Patent
U.S. Patent and Trademark Office issued a Notice of Allowance for Patent Application No. 17/000,768 titled, "Method for Generating a ZIKV Immune Response Utilizing a Recombinant Modified Vaccinia Ankara Vector
GeoVax Receives Notice Of Allowance For U.S. Patent Titled ‘METHOD OF GENERATING A ZIKV IMMUNE RESPONSE UTILIZING A RECOMBINANT MODIFIED VACCINIA ANKARA VECTOR ENCODING THE NS1 PROTEIN’
https://patentcenter.uspto.gov/#!/applications/17000768/ifw/docs
CG Capital Initiates Coverage On Geovax Labs with Outperform Rating, Announces Price Target of $6
CG Capital initiates coverage on Geovax Labs (NASDAQ:GOVX) with a Outperform rating and announces Price Target of $6.